Sanofi ADR (SNY) Stock: A Closer Look at the Market Potential

The price-to-earnings ratio for Sanofi ADR (NASDAQ: SNY) is above average at 20.70x, Company’s 36-month beta value is 0.62.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”

The public float for SNY is 2.50B, and currently, short sellers hold a 0.18% ratio of that floaft. The average trading volume of SNY on April 03, 2024 was 1.85M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

SNY) stock’s latest price update

Sanofi ADR (NASDAQ: SNY) has seen a rise in its stock price by 0.81 in relation to its previous close of 47.70. However, the company has experienced a -3.35% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-25 that Sanofi has underperformed the U.S. stock market lately but now offers one of the smartest growth-at-a-reasonable-price setups in Big Pharma. Sanofi is best known for its patented drug Dupixent and numerous vaccines manufactured for global use, which generate a significant portion of its revenue. The company has a stable dividend proposition, strong balance sheet, and better-than-average potential for earnings growth in the future.

SNY’s Market Performance

SNY’s stock has fallen by -3.35% in the past week, with a monthly rise of 1.98% and a quarterly drop of -3.83%. The volatility ratio for the week is 1.54% while the volatility levels for the last 30 days are 1.27% for Sanofi ADR The simple moving average for the last 20 days is -0.40% for SNY stock, with a simple moving average of -4.77% for the last 200 days.

Analysts’ Opinion of SNY

Many brokerage firms have already submitted their reports for SNY stocks, with Morgan Stanley repeating the rating for SNY by listing it as a “Equal-Weight.” The predicted price for SNY in the upcoming period, according to Morgan Stanley is $55 based on the research report published on January 23, 2024 of the current year 2024.

SNY Trading at -0.02% from the 50-Day Moving Average

After a stumble in the market that brought SNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.84% of loss for the given period.

Volatility was left at 1.27%, however, over the last 30 days, the volatility rate increased by 1.54%, as shares surge +0.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.84% lower at present.

During the last 5 trading sessions, SNY fell by -3.80%, which changed the moving average for the period of 200-days by -7.59% in comparison to the 20-day moving average, which settled at $48.30. In addition, Sanofi ADR saw -3.31% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for SNY

Current profitability levels for the company are sitting at:

  • 0.22 for the present operating margin
  • 0.66 for the gross margin

The net margin for Sanofi ADR stands at 0.14. The total capital return value is set at 0.12. Equity return is now at value 7.22, with 4.25 for asset returns.

Based on Sanofi ADR (SNY), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at 1.02. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is 12.3.

Currently, EBITDA for the company is 12.96 billion with net debt to EBITDA at 0.59. When we switch over and look at the enterprise to sales, we see a ratio of 2.12. The receivables turnover for the company is 5.17for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.27.

Conclusion

In a nutshell, Sanofi ADR (SNY) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts